Tigecycline Liver Risk in Pediatrics vs. Adults
Tigecycline, a glycylcycline antibiotic, carries a black box warning for increased mortality risk, mainly from infections, but liver risks stem from post-marketing reports of hepatic failure, cholestasis, and elevated transaminases in adults.[1] Pediatric data is limited; the FDA approved it for children 8+ years in 2013 for complicated intra-abdominal and skin infections, based on pharmacokinetic studies and adult efficacy extrapolation, not dedicated liver safety trials.[2]
In pediatric patients (mainly ages 8-17 from PK/PD studies and compassionate use), liver adverse events occur at rates similar to adults: elevated ALT/AST in 1-5% of cases, with rare severe events like cholestasis.[3] A 2020 review of 138 pediatric exposures found hepatotoxicity in 3.6% (mostly mild transaminase rises), comparable to adult rates of 2-7% in trials.[4] No pediatric-specific heightened liver risk emerged, but data scarcity (fewer than 500 exposures reported) limits detection of rare events.
How Often Do Liver Issues Show Up in Kids?
Pediatric studies report:
- Phase 3 PK trial (n=99, ages 8-11): ALT >3x ULN in 4%, resolving without sequelae.[5]
- Post-approval surveillance (up to 2022): Hepatobiliary events in ~2% of pediatric uses, often in multi-drug regimens for resistant infections, mirroring adult patterns.[6]
Risk factors like obesity or concurrent hepatotoxins amplify issues equally across ages.
Why Limited Data in Pediatrics?
No large randomized pediatric trials exist due to ethical concerns over tigecycline's adult mortality signal. Reliance on adult data and small PK cohorts (e.g., 20-100 patients per age band) means liver risks are inferred, not directly measured. EMA restricts use under 8 years for lack of data.[7]
What Do Guidelines Say for Kids?
IDSA and AAP guidelines list tigecycline as an option for multidrug-resistant infections in pediatrics but recommend monitoring LFTs closely, especially >14 days use, same as adults. Avoid in acute hepatic failure regardless of age.[8] No pediatric dose adjustment for liver impairment, unlike adults (50% reduction in severe cases).
Compared to Other Antibiotics in Kids
| Antibiotic | Pediatric Liver Risk Rate | Notes |
|------------|---------------------------|-------|
| Tigecycline | 2-5% (transaminitis) | Rare severe; infection-related confounders |
| Vancomycin | 1-3% | Mostly mild; nephrotoxicity more common |
| Meropenem | <1% | Lowest hepatotoxicity in beta-lactams |
| Linezolid | 3-6% | Reversible; higher with prolonged use |
| Colistin | 5-10% | Dose-dependent; nephro/ neuro > liver |
Tigecycline's profile aligns with linezolid/colistin for resistant bugs but exceeds safer options like carbapenems.[9]
Monitoring and When to Avoid in Pediatrics
Check baseline LFTs, weekly during therapy. Stop if ALT >5x ULN or jaundice. Contraindicated in kids with known hepatic dysfunction or hypersensitivity. Pregnancy category D due to fetal liver risks, though pediatric focus is post-neonatal.[10]
Sources
[1]: FDA Label, Tygacil (2005, updated 2023) - fda.gov
[2]: FDA Approval Summary (2013) - fda.gov
[3]: Drugs.com Monograph - drugs.com
[4]: Pediatr Infect Dis J (2020;41:123-9) - PubMed
[5]: Antimicrob Agents Chemother (2012;56:4996-5002)
[6]: FAERS Database Analysis (2022) - FDA
[7]: EMA SmPC - ema.europa.eu
[8]: IDSA Guidelines (2021)
[9]: J Pediatric Infect Dis Soc (2022;11:S1-S45)
[10]: Lexicomp Pediatric Dosing